论文部分内容阅读
目的:探讨血脂康对高血压病人胰岛素水平的影响。方法:60例高血压合并高胰岛素血症病人在原有降压治疗,改善生活模式的基础上随机分为血脂康治疗组和空白对照组。治疗组投用血脂康胶囊1.8g/日,8周,两组均观察血压、血脂水平,糖耐量试验及胰岛素释放试验。结果:血脂康组治疗前、后餐后2小时胰岛素水平分别为153.1±19.9μIU.ml和93.1士31.5μIU/ml,治疗后明显下降(P<0.05)。8周后治疗组餐后2小时血糖下降1.4±0.4mmol/L,空白对照组下降0.9±0.3mmol/L,血脂康组血糖水平略低于对照组,但无显著性差异(P>0.05)。结论:血脂康能在不降低血糖的情况下,降低高血压合并高胰岛素血症病人的胰岛素水平。
Objective: To investigate the effect of Xuezhikang on the insulin level in hypertensive patients. Methods: Sixty patients with hypertension and hyperinsulinemia were randomly divided into Xuezhikang treatment group and blank control group on the basis of the original antihypertensive treatment and lifestyle improvement. The treatment group was given Xuezhikang capsules 1.8g / day, 8 weeks, both groups were observed blood pressure, blood lipid levels, glucose tolerance test and insulin release test. Results: The levels of insulin in Xuezhikang group before and after meal were 153.1 ± 19.9μIU.ml and 93.1 ± 31.5μIU / ml respectively, which were significantly decreased after treatment (P <0.05). After 8 weeks, the blood glucose of the treatment group decreased 1.4 ± 0.4mmol / L 2h after meal and decreased 0.9 ± 0.3mmol / L in the blank control group, but slightly lower than that of the control group (P 0.05) . Conclusion: Xuezhikang can reduce the insulin level in patients with hypertension and hyperinsulinemia without lowering blood glucose.